AAAAAA

   
Results: 1-25 | 26-48 |
Results: 26-48/48
EXPRESSION OF THE C-MPL RECEPTOR ON LEUKEMIC BLASTS FROM PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML)
Authors: BERNSTEIN SH BAER MR STEWART C SLACK JL LAWRENCE D HERZIG GP BLOOMFIELD CD WETZIER M
Citation: Sh. Bernstein et al., EXPRESSION OF THE C-MPL RECEPTOR ON LEUKEMIC BLASTS FROM PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML), Blood, 86(10), 1995, pp. 169-169
SERIAL DETERMINATION OF THROMBOPOIETIN (TPO), IL-3, IL-6, IL-11 AND LEUKEMIA INHIBITORY FACTOR (LIF) LEVELS IN PATIENTS UNDERGOING CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA (AML)
Authors: BERNSTEIN SH BAER MR LAWRENCE D HERZIG GP BLOOMFIELD CD WETZLER M
Citation: Sh. Bernstein et al., SERIAL DETERMINATION OF THROMBOPOIETIN (TPO), IL-3, IL-6, IL-11 AND LEUKEMIA INHIBITORY FACTOR (LIF) LEVELS IN PATIENTS UNDERGOING CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA (AML), Blood, 86(10), 1995, pp. 170-170
DOSE-ESCALATION STUDY OF PIXY321 POST AUTOLOGOUS BONE-MARROW TRANSPLANT (BMT) FOR HODGKINS-DISEASE (HD) OR NON-HODGKINS-LYMPHOMA (NHL)
Authors: NANTEL SH BERNSTEIN SH STEVENS DA FAY JW HERZIG RH PHILLIPS GL HERZIG GP GARRISON L
Citation: Sh. Nantel et al., DOSE-ESCALATION STUDY OF PIXY321 POST AUTOLOGOUS BONE-MARROW TRANSPLANT (BMT) FOR HODGKINS-DISEASE (HD) OR NON-HODGKINS-LYMPHOMA (NHL), Blood, 86(10), 1995, pp. 876-876
THE PARTIAL TANDEM DUPLICATION OF ALL1 IS A RECURRENT NOVEL MOLECULARDEFECT IN ACUTE MYELOID-LEUKEMIA (AML) WITH TRISOMY-11
Authors: STROUT MP CALIGIURI MA SCHICHMAN SA MROZEK K HERZIG GP ARTHUR DC HEINONEN K KNUUTILA S NOUSIAINEN T RUUTU T BLOCK AW CROCE CM BLOOMFIELD CD
Citation: Mp. Strout et al., THE PARTIAL TANDEM DUPLICATION OF ALL1 IS A RECURRENT NOVEL MOLECULARDEFECT IN ACUTE MYELOID-LEUKEMIA (AML) WITH TRISOMY-11, Blood, 86(10), 1995, pp. 1702-1702
ACUTE MYELOID-LEUKEMIA (AML) BLAST CELL-PROLIFERATION AND DIFFERENTIATION IN RESPONSE TO MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (MGDF)
Authors: SLACK JL BAER MR BERNSTEIN SH STEWART C LAWRENCE D HERZIG GP BLOOMFIELD CD WETZIER M
Citation: Jl. Slack et al., ACUTE MYELOID-LEUKEMIA (AML) BLAST CELL-PROLIFERATION AND DIFFERENTIATION IN RESPONSE TO MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (MGDF), Blood, 86(10), 1995, pp. 2070-2070
PERSISTENCE OF THE T(8-21) FUSION TRANSCRIPT FOLLOWING ALLOGENEIC (ALLO) BONE-MARROW TRANSPLANTATION (BMT) FOR ACUTE MYELOID-LEUKEMIA (AML)
Authors: JURLANDER J CALIGIURI MA STROUT MP BALL ED FREILAHR DA HOFFMANN L OBERKIRCHER AR CHRISTIANSEN NP BLOCK AW HERZIG GP BLOOMFIELD CD
Citation: J. Jurlander et al., PERSISTENCE OF THE T(8-21) FUSION TRANSCRIPT FOLLOWING ALLOGENEIC (ALLO) BONE-MARROW TRANSPLANTATION (BMT) FOR ACUTE MYELOID-LEUKEMIA (AML), Blood, 86(10), 1995, pp. 2262-2262
A PHASE-I NOVEL ALKYLATING AGENT (AA), ADOZELESIN PATIENTS (PTS) WITHREFRACTORY HEMATOLOGIC MALIGNANCIES (HM)
Authors: STONE RM PIRO ID SAVEN A BERG DT BRYAN WJ FAY JW HERZIG GP HERZIG RH SHIELDS AF COLEMAN BS LEE EJ
Citation: Rm. Stone et al., A PHASE-I NOVEL ALKYLATING AGENT (AA), ADOZELESIN PATIENTS (PTS) WITHREFRACTORY HEMATOLOGIC MALIGNANCIES (HM), Blood, 86(10), 1995, pp. 3116-3116
ALL IN 1ST REMISSION - RAND-DELPHI ANALYSIS OF APPROPRIATENESS OF BONE-MARROW TRANSPLANTS
Authors: GALE RP HERZIG GP HOCKING WG HOROWITZ MM KEATING A KEMPIN S LINKER CA PARK ER RAI K SCHIFFER CA WEISDORF DJ DUBOIS R WIERNIK PH
Citation: Rp. Gale et al., ALL IN 1ST REMISSION - RAND-DELPHI ANALYSIS OF APPROPRIATENESS OF BONE-MARROW TRANSPLANTS, Blood, 86(10), 1995, pp. 3772-3772
AML IN 1ST REMISSION - RAND-DELPHI ANALYSIS OF APPROPRIATENESS OF BONE-MARROW TRANSPLANTS
Authors: GALE RP HERZIG GP HOCKING WG HOROWITZ MM KEATING A KEMPIN S LINKER CA PARK ER RAI K SCHIFFER CA WEISDORF DJ DUBOIS R WIERNIK PH
Citation: Rp. Gale et al., AML IN 1ST REMISSION - RAND-DELPHI ANALYSIS OF APPROPRIATENESS OF BONE-MARROW TRANSPLANTS, Blood, 86(10), 1995, pp. 3773-3773
CML IN CHRONIC PHASE - RAND-DELPHI ANALYSIS OF APPROPRIATENESS OF BONE-MARROW TRANSPLANTS
Authors: GALE RP HERZIG GP HOCKING WG HOROWITZ MM KEATING A KEMPIN S LINKER CA PARK ER RAI K SCHIFFER CA WEISDORF DJ DUBOIS R WIERNIK PH
Citation: Rp. Gale et al., CML IN CHRONIC PHASE - RAND-DELPHI ANALYSIS OF APPROPRIATENESS OF BONE-MARROW TRANSPLANTS, Blood, 86(10), 1995, pp. 3774-3774
HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICANMARROW TRANSPLANT GROUP
Authors: BROWN RA WOLFF SN FAY JW PINEIRO L COLLINS RH LYNCH JP STEVENS D GREER J HERZIG RH HERZIG GP
Citation: Ra. Brown et al., HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICANMARROW TRANSPLANT GROUP, Blood, 85(5), 1995, pp. 1391-1395
MOLECULAR REARRANGEMENT OF THE ALL-1 GENE IN ACUTE MYELOID-LEUKEMIA WITHOUT CYTOGENETIC EVIDENCE OF 11Q23 CHROMOSOMAL TRANSLOCATIONS
Authors: CALIGIURI MA SCHICHMAN SA STROUT MP MROZEK K BAER MR FRANKEL SR BARCOS M HERZIG GP CROCE CM BLOOMFIELD CD
Citation: Ma. Caligiuri et al., MOLECULAR REARRANGEMENT OF THE ALL-1 GENE IN ACUTE MYELOID-LEUKEMIA WITHOUT CYTOGENETIC EVIDENCE OF 11Q23 CHROMOSOMAL TRANSLOCATIONS, Cancer research, 54(2), 1994, pp. 370-373
HIGH-DOSE CYTOSINE-ARABINOSIDE (HDAC) DAUNORUBICIN (DNR) INDUCTION FOLLOWED BY HIGH-DOSE ETOPOSIDE (VP) CYCLOPHOSPHAMIDE (CY) CONSOLIDATIONFOR PATIENTS (PTS) WITH AML
Authors: BROWN RA WOLFF S FAY J PINEIRO L GREER J LYNCH J COLLINS R STEVENS D HERZIG R HERZIG GP
Citation: Ra. Brown et al., HIGH-DOSE CYTOSINE-ARABINOSIDE (HDAC) DAUNORUBICIN (DNR) INDUCTION FOLLOWED BY HIGH-DOSE ETOPOSIDE (VP) CYCLOPHOSPHAMIDE (CY) CONSOLIDATIONFOR PATIENTS (PTS) WITH AML, Blood, 84(10), 1994, pp. 10000146-10000146
MULTIPARAMETER FLOW-CYTOMETRY (MFC) MONITORS RESIDUAL DISEASE (RD) DURING COMPLETE REMISSION (CR) OF ACUTE MYELOID-LEUKEMIA (AML)
Authors: BAER MR LO CH MEANS J SALZMAN G FRANKEL SR LAWRENCE D MOORE JO HERZIG GP SCHIFFER CA BLOOMFIELD CD STEWART CC
Citation: Mr. Baer et al., MULTIPARAMETER FLOW-CYTOMETRY (MFC) MONITORS RESIDUAL DISEASE (RD) DURING COMPLETE REMISSION (CR) OF ACUTE MYELOID-LEUKEMIA (AML), Blood, 84(10), 1994, pp. 10000307-10000307
ACUTE MYELOID-LEUKEMIA WITH 11Q23 CHROMOSOME ALL-1 GENE REARRANGEMENTS DOES NOT EXHIBIT MIXED LINEAGE ANTIGEN EXPRESSION BY MULTIPARAMETER FLOW-CYTOMETRY
Authors: BAER MR STEWART CC LAWRENCE D ARTHUR DC DAVEY FR MROZEK K CALIGIURI MA HERZIG GP SCHIFFER CA BLOOMFIELD CD
Citation: Mr. Baer et al., ACUTE MYELOID-LEUKEMIA WITH 11Q23 CHROMOSOME ALL-1 GENE REARRANGEMENTS DOES NOT EXHIBIT MIXED LINEAGE ANTIGEN EXPRESSION BY MULTIPARAMETER FLOW-CYTOMETRY, Blood, 84(10), 1994, pp. 10000308-10000308
HIGH-DOSE CYTARABINE, IDARUBICIN, AND GRANULOCYTE-COLONY-STIMULATING FACTOR REMISSION INDUCTION THERAPY FOR PREVIOUSLY UNTREATED DE-NOVO AND SECONDARY ADULT ACUTE MYELOID-LEUKEMIA
Authors: BAER MR CHRISTIANSEN NP FRANKEL SR BRUNETTO VL MROZEK K BLOOMFIELD CD HERZIG GP
Citation: Mr. Baer et al., HIGH-DOSE CYTARABINE, IDARUBICIN, AND GRANULOCYTE-COLONY-STIMULATING FACTOR REMISSION INDUCTION THERAPY FOR PREVIOUSLY UNTREATED DE-NOVO AND SECONDARY ADULT ACUTE MYELOID-LEUKEMIA, Seminars in oncology, 20(6), 1993, pp. 6-12
HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, TOTAL-BODY IRRADIATION (VP CY/TBI) AND ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) FOR PATIENTS WITH RESISTANT ACUTE MYELOID-LEUKEMIA (AML) - A PHASE-I-II TRIAL BY THE NORTH-AMERICAN MARROW TRANSPLANT GROUP/
Authors: BROWN RA WOLFF S FAY J PINEIRO L GREEN J LYNCH J COLLINS R STEVENS D HERZIG R HERZIG GP
Citation: Ra. Brown et al., HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, TOTAL-BODY IRRADIATION (VP CY/TBI) AND ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) FOR PATIENTS WITH RESISTANT ACUTE MYELOID-LEUKEMIA (AML) - A PHASE-I-II TRIAL BY THE NORTH-AMERICAN MARROW TRANSPLANT GROUP/, Blood, 82(10), 1993, pp. 10000166-10000166
NATURAL-KILLER (NK) CELL-ACTIVITY FOLLOWING DOSE-INTENSIVE CHEMOTHERAPY (CT)
Authors: LAUGHLIN M LOFTUS J HERZIG GP CALIGIURI T CALIGIURI M
Citation: M. Laughlin et al., NATURAL-KILLER (NK) CELL-ACTIVITY FOLLOWING DOSE-INTENSIVE CHEMOTHERAPY (CT), Blood, 82(10), 1993, pp. 10000242-10000242
SEQUENTIAL ADMINISTRATION OF INTERLEUKIN-3 (RHIL-3) AND RHGM-CSF FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION - AN UPDATE OF THE PHASE-I II TRIAL/
Authors: FAY JW FELSER J LAZARUS HM HERZIG R SAEZ R STEVENS D COLLINS RH PINERO L COOPER B HERZIG GP CAMPION M DICESARE J BERNSTEIN SH
Citation: Jw. Fay et al., SEQUENTIAL ADMINISTRATION OF INTERLEUKIN-3 (RHIL-3) AND RHGM-CSF FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION - AN UPDATE OF THE PHASE-I II TRIAL/, Blood, 82(10), 1993, pp. 10000287-10000287
IN-VIVO RECOMBINANT HUMAN G-CSF PRIMING IN PREVIOUSLY UNTREATED ACUTEMYELOID-LEUKEMIA
Authors: BAER MR BERNSTEIN SH BRUNETTO VL MINDERMAN H RUSTUM Y BLOCK AW MROZEK K BLOOMFIELD CD HERZIG GP
Citation: Mr. Baer et al., IN-VIVO RECOMBINANT HUMAN G-CSF PRIMING IN PREVIOUSLY UNTREATED ACUTEMYELOID-LEUKEMIA, Blood, 82(10), 1993, pp. 10000328-10000328
PCR AMPLIFICATION OF MINISATELLITES FOR THE EVALUATION OF HEMATOPOIETIC CHIMERISM FOLLOWING ALLOGENEIC BMT - DESCRIPTION OF AN EFFICIENT AND HIGHLY INFORMATIVE METHOD
Authors: OBERKIRCHER AR STROUT MP HERZIG GP CALIGIURI MA
Citation: Ar. Oberkircher et al., PCR AMPLIFICATION OF MINISATELLITES FOR THE EVALUATION OF HEMATOPOIETIC CHIMERISM FOLLOWING ALLOGENEIC BMT - DESCRIPTION OF AN EFFICIENT AND HIGHLY INFORMATIVE METHOD, Blood, 82(10), 1993, pp. 10000427-10000427
MEASUREMENT OF LINEAGE-COMMITTED CD34-MARROW PROGENITORS IN ALLOGENEIC TRANSPLANTATION( BONE)
Authors: LAUGHLIN M CHRISTIANSEN NP STEWART CC NETTLETON A BONNEY D HERZIG GP
Citation: M. Laughlin et al., MEASUREMENT OF LINEAGE-COMMITTED CD34-MARROW PROGENITORS IN ALLOGENEIC TRANSPLANTATION( BONE), Blood, 82(10), 1993, pp. 10000650-10000650
HIGH-DOSE WEEKLY INTRAVENOUS IMMUNOGLOBULIN TO PREVENT INFECTIONS IN PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION OR SEVERE MYELOSUPPRESSIVE THERAPY - A STUDY OF THE AMERICAN-BONE-MARROW-TRANSPLANT-GROUP
Authors: WOLFF SN FAY JW HERZIG RH GREER JP DUMMER S BROWN RA COLLINS RH STEVENS DA HERZIG GP
Citation: Sn. Wolff et al., HIGH-DOSE WEEKLY INTRAVENOUS IMMUNOGLOBULIN TO PREVENT INFECTIONS IN PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION OR SEVERE MYELOSUPPRESSIVE THERAPY - A STUDY OF THE AMERICAN-BONE-MARROW-TRANSPLANT-GROUP, Annals of internal medicine, 118(12), 1993, pp. 937-942
Risultati: 1-25 | 26-48 |